Page 1 | Search Results | Blood | American Society of Hematology

Skip to Main Content

Skip Nav Destination

1-3 of 3

Sort by

Sort Order Select

Journal Articles

Clinical Efficacy of Polatuzumab Vedotin in Patients with Relapsed/Refractory Large B-Cell Lymphoma after Standard of Care Axicabtagene Ciloleucel

Paolo Strati, MD, Grace Watson, Sandra B. Horowitz, Pharm.D., Ranjit Nair, MD, Maria Alma Rodriguez, MD, Raphael Eric Steiner, MD, Luis Fayad, Jason R. Westin, MD, Sattva S. Neelapu, MD

Blood (2020) 136 (Supplement 1): 16–17.

https://doi.org/10.1182/blood-2020-135835

Published: 2020

Journal Articles

Hyperfractionated Cyclophosphamide-Dexamethasone (HyperCy-Dex) with or without Carfilzomib (Car) in Patients (pts) with Multiple Myeloma (MM)

Erin K. Yeung, Pharm.D., Brian R. Primeaux, Pharm.D., Sandra B. Horowitz, Pharm.D., Brandon R. Shank, Irene Y. Lee, Gregory P. Kaufman, MD, Hans C. Lee, MD, Elisabet E. Manasanch, MD, Krina K. Patel, MD, Robert Z. Orlowski, MDPhD, Donna M. Weber, MD, Sheeba K. Thomas, MD

Blood (2020) 136 (Supplement 1): 19–20.

https://doi.org/10.1182/blood-2020-137704

Published: 2020

Journal Articles

Descriptive Analysis of Isatuximab Use Following Prior Daratumumab in Patients with Relapsed/Refractory Multiple Myeloma

Melody R Becnel, MD, Sandra B. Horowitz, Pharm.D., Sheeba K. Thomas, MD, Swami P. Iyer, MD, Krina K. Patel, MD, Elisabet E. Manasanch, MD, Donna M. Weber, MD, Gregory P. Kaufman, MD, Hans C. Lee, MD, Robert Z. Orlowski, MDPhD

Blood (2020) 136 (Supplement 1): 20–21.

https://doi.org/10.1182/blood-2020-140526

Published: 2020